Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Could the Cost of Cancer Immunotherapy Overshadow Its Effectiveness?

Could the Cost of Cancer Immunotherapy Overshadow Its Effectiveness?

One important issue concerning immunotherapy, which has become an indispensable part of cancer treatment despite having a history of only a few years, is its cost. The costs of treatments involving these drugs intimidate even the wealthiest countries. As physicians, while we are excited that these drugs produce significant survival differences in various cancers, we are also concerned about how feasible their use in clinical practice will be because of their extremely high cost.

One of the topics at the Best of ASCO 2015 Istanbul meeting, which began today, was barriers to accessing new treatments in oncology. During the discussion, we observed that our colleagues attending from abroad shared similar concerns about immunotherapy costs.

For example, in the squamous cell subtype of lung cancer, a drug (nivolumab) produced a survival difference of more than 3 months for the first time in many years, but treating even a single patient with these drugs costs hundreds of thousands of lira. Moreover, these new-generation immunotherapy drugs do not yet promise a cure (complete recovery from the disease), but only prolong survival. Although we wholeheartedly believe and advocate that every patient deserves the best treatment, will we be able to afford these treatments for a cancer with as many patients as lung cancer?

When pharmaceutical companies are asked why new drugs are so expensive, the very high cost of drug development is the standard response. Although this answer has some justification, is it true that when pharmaceutical companies recognize that a new drug they have developed is effective and that choosing these drugs is inevitable, they market them at prices far above their production costs?

The Greatest Barrier to Accessing New Treatments: Cost!

One of the discussion subtopics was the question, can the cost barrier be overcome ? Countries acting together to negotiate more firmly with pharmaceutical companies, producing our own biosimilar drugs, and ensuring participation in more clinical trials were some of the proposed solutions...

Overcoming the barriers to our patients' access to the best treatments does not depend solely on the responsibility, common sense, and problem-solving abilities of governments, drug developers, and physicians; perhaps it depends most on increased public awareness. For this reason, in our articles this week, we have tried to explain many aspects of cancer immunotherapy, a subject we will hear about and discuss frequently in the coming period.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Could the Cost of Cancer Immunotherapy Overshadow Its Effectiveness?

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy